Anti-ASC Antibody Compositions for Inflammasome-Driven Lung Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need to elucidate the pathomechanisms of lung inflammation caused by traumatic brain injury (TBI) and other conditions, as well as develop therapeutic compositions to treat and prevent lung inflammation, as existing treatments are scarce and the molecular mechanisms underlying TBI-induced lung injury remain poorly defined.
Innovation Solution
Development of monoclonal antibodies or antibody fragments that specifically bind to Apoptosis-associated Speck-like protein containing a Caspase Activating Recruitment Domain (ASC), targeting specific epitopes and modulating ASC activity to inhibit inflammasome activation, thereby reducing inflammatory cytokine levels and inflammation in conditions such as TBI, stroke, spinal cord injury, and various inflammatory and metabolic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for lung inflammation, then treatment availability is limited, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent employs monoclonal antibodies with specific binding affinities to ASC protein, utilizing parameter changes in antibody design (specificity, affinity, isotype) to achieve reliable therapeutic efficacy while maintaining versatility across different administration routes and disease conditions
Solution Approach 2:
The anti-ASC monoclonal antibodies are designed to be universally applicable across multiple disease conditions (TBI, stroke, spinal cord injury, autoimmune diseases, metabolic diseases) and can be administered through multiple routes (intracerebroventricular, intraperitoneal, intravenous, inhalation), resolving the contradiction between therapeutic efficacy and treatment availability
2Loss of information
If existing therapies are applied for TBI-induced lung injury, then treatment options are scarce, but molecular mechanism understanding is insufficient
Solution Approach 1:
The patent performs preliminary action by first elucidating the molecular mechanism of TBI-induced lung injury through inflammasome activation and ASC protein involvement, then develops targeted anti-ASC monoclonal antibodies based on this understanding, thereby converting mechanism knowledge into therapeutic options
Solution Approach 2:
The anti-ASC monoclonal antibodies serve as intermediaries that bridge the gap between molecular mechanism understanding and clinical treatment, specifically targeting the inflammasome pathway to reduce inflammatory cytokine release and treat lung injury
3Reliability
If inflammasome activation occurs in response to injury, then inflammatory response is activated, but tissue damage is exacerbated
Solution Approach 1:
The patent extracts and neutralizes the harmful aspect of inflammasome activation by using monoclonal antibodies to specifically bind and inhibit ASC protein, thereby preventing the formation of the inflammasome complex and the subsequent release of inflammatory cytokines like IL-1β and IL-18, reducing tissue damage while maintaining necessary immune function
Data Source
AI summary
The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating inflammasome related diseases or conditions.